“…Hence, where plasmid gene transfer into skeletal muscle is carried out for induction of an immune response (genetic vaccination), or for systemic delivery (eg apoE, factor IX, erythropoietin), the damage caused when using current electrotransfer protocols may not be significantly detrimental. 11,[13][14][15] However, for treatment of muscle disease by gene replacement, for example, in the case of muscular dystrophies, it is essential to ensure the survival of muscle fibres while maximising the number of transfected fibres.…”